Education
About Us
Working with TipRanks
Follow Us
Jane A Gross Insider Profile
11 Followers
Jane A Gross, SVP & Chief Scientific Officer at Aptevo Therapeutics, holds 9.75K shares in aTyr Pharma (Ticker: ATYR), holds 109.58K shares in Aptevo Therapeutics (Ticker: APVO). Most recently, Jane A Gross Bought ― shares of aTyr Pharma on Mar 17, 2025 for an estimated value of $15.00K.
Jane A Gross has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Jane A Gross holds in companies
Most Profitable Insider Trade
The most profitable trade made by Jane A Gross
Jane A Gross's Trading History
Aptevo Therapeutics
Mar 04, 2019
SVP & Chief Scientific Officer
Uninformative Buy
10.09K
$214.78K
aTyr Pharma
Mar 17, 2025
Director
Informative Buy
15.00K
$47.97K
List of latest transactions for each holding click on a transaction to see Jane A Gross's performance on stock
You May Also Like
Jane A Gross insider profile FAQ
What is the percentage of profitable transactions made by Jane A Gross?
The percentage of profitable transactions made by Jane A Gross is ―.
What is the average return per transaction made by Jane A Gross?
The average return per transaction made by Jane A Gross is ―.
What stocks does Jane A Gross hold?
Jane A Gross holds: APVO, ATYR stocks.
What was Jane A Gross’s latest transaction?
Jane A Gross latest transaction was an Informative Buy of $15.00K.
What was Jane A Gross's most profitable transaction?
Jane A Gross’s most profitable transaction was an Informative Buy of ATYR stock on March 17, 2025. The return on the trade was 22.10%.
What is Jane A Gross's role in Aptevo Therapeutics?
Jane A Gross's role in Aptevo Therapeutics is SVP & Chief Scientific Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.